Bladder cancer

Oner Sanli, Jakub Dobruch, Margaret A. Knowles, Maximilian Burger, Mehrdad Alemozaffar, Matthew E. Nielsen, Yair Lotan

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours. The two subtypes have unique pathological features and different molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers of muscle-invasive bladder cancer (MIBC) as well as subtypes of MIBC with distinct characteristics and therapeutic responses. For non-muscle-invasive bladder cancer (NMIBC), intravesical therapies (primarily Bacillus Calmette-Guérin (BCG)) with maintenance are the main treatments to prevent recurrence and progression after initial TURBT; additional therapies are needed for those who do not respond to BCG. For localized MIBC, optimizing care and reducing morbidity following cystectomy are important goals. In metastatic disease, advances in our genetic understanding of bladder cancer and in immunotherapy are being translated into new therapies.

Original languageEnglish (US)
Article number17022
JournalNature Reviews Disease Primers
Volume3
DOIs
StatePublished - Apr 13 2017

Fingerprint

Urinary Bladder Neoplasms
Muscles
Bacillus
Therapeutics
Morbidity
Neoplasms
Atlases
Cystectomy
Environmental Exposure
Hematuria
Occupational Exposure
Carcinogens
Immunotherapy
Tobacco
Maintenance
Genome
Costs and Cost Analysis
Recurrence
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017). Bladder cancer. Nature Reviews Disease Primers, 3, [17022]. https://doi.org/10.1038/nrdp.2017.22

Bladder cancer. / Sanli, Oner; Dobruch, Jakub; Knowles, Margaret A.; Burger, Maximilian; Alemozaffar, Mehrdad; Nielsen, Matthew E.; Lotan, Yair.

In: Nature Reviews Disease Primers, Vol. 3, 17022, 13.04.2017.

Research output: Contribution to journalArticle

Sanli, O, Dobruch, J, Knowles, MA, Burger, M, Alemozaffar, M, Nielsen, ME & Lotan, Y 2017, 'Bladder cancer', Nature Reviews Disease Primers, vol. 3, 17022. https://doi.org/10.1038/nrdp.2017.22
Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME et al. Bladder cancer. Nature Reviews Disease Primers. 2017 Apr 13;3. 17022. https://doi.org/10.1038/nrdp.2017.22
Sanli, Oner ; Dobruch, Jakub ; Knowles, Margaret A. ; Burger, Maximilian ; Alemozaffar, Mehrdad ; Nielsen, Matthew E. ; Lotan, Yair. / Bladder cancer. In: Nature Reviews Disease Primers. 2017 ; Vol. 3.
@article{88a5166509cc48819b3b7054e76d3431,
title = "Bladder cancer",
abstract = "Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours. The two subtypes have unique pathological features and different molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers of muscle-invasive bladder cancer (MIBC) as well as subtypes of MIBC with distinct characteristics and therapeutic responses. For non-muscle-invasive bladder cancer (NMIBC), intravesical therapies (primarily Bacillus Calmette-Gu{\'e}rin (BCG)) with maintenance are the main treatments to prevent recurrence and progression after initial TURBT; additional therapies are needed for those who do not respond to BCG. For localized MIBC, optimizing care and reducing morbidity following cystectomy are important goals. In metastatic disease, advances in our genetic understanding of bladder cancer and in immunotherapy are being translated into new therapies.",
author = "Oner Sanli and Jakub Dobruch and Knowles, {Margaret A.} and Maximilian Burger and Mehrdad Alemozaffar and Nielsen, {Matthew E.} and Yair Lotan",
year = "2017",
month = "4",
day = "13",
doi = "10.1038/nrdp.2017.22",
language = "English (US)",
volume = "3",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Bladder cancer

AU - Sanli, Oner

AU - Dobruch, Jakub

AU - Knowles, Margaret A.

AU - Burger, Maximilian

AU - Alemozaffar, Mehrdad

AU - Nielsen, Matthew E.

AU - Lotan, Yair

PY - 2017/4/13

Y1 - 2017/4/13

N2 - Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours. The two subtypes have unique pathological features and different molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers of muscle-invasive bladder cancer (MIBC) as well as subtypes of MIBC with distinct characteristics and therapeutic responses. For non-muscle-invasive bladder cancer (NMIBC), intravesical therapies (primarily Bacillus Calmette-Guérin (BCG)) with maintenance are the main treatments to prevent recurrence and progression after initial TURBT; additional therapies are needed for those who do not respond to BCG. For localized MIBC, optimizing care and reducing morbidity following cystectomy are important goals. In metastatic disease, advances in our genetic understanding of bladder cancer and in immunotherapy are being translated into new therapies.

AB - Bladder cancer is a highly prevalent disease and is associated with substantial morbidity, mortality and cost. Environmental or occupational exposures to carcinogens, especially tobacco, are the main risk factors for bladder cancer. Most bladder cancers are diagnosed after patients present with macroscopic haematuria, and cases are confirmed after transurethral resection of bladder tumour (TURBT), which also serves as the first stage of treatment. Bladder cancer develops via two distinct pathways, giving rise to non-muscle-invasive papillary tumours and non-papillary (solid) muscle-invasive tumours. The two subtypes have unique pathological features and different molecular characteristics. Indeed, The Cancer Genome Atlas project identified genetic drivers of muscle-invasive bladder cancer (MIBC) as well as subtypes of MIBC with distinct characteristics and therapeutic responses. For non-muscle-invasive bladder cancer (NMIBC), intravesical therapies (primarily Bacillus Calmette-Guérin (BCG)) with maintenance are the main treatments to prevent recurrence and progression after initial TURBT; additional therapies are needed for those who do not respond to BCG. For localized MIBC, optimizing care and reducing morbidity following cystectomy are important goals. In metastatic disease, advances in our genetic understanding of bladder cancer and in immunotherapy are being translated into new therapies.

UR - http://www.scopus.com/inward/record.url?scp=85017451219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017451219&partnerID=8YFLogxK

U2 - 10.1038/nrdp.2017.22

DO - 10.1038/nrdp.2017.22

M3 - Article

C2 - 28406148

AN - SCOPUS:85017451219

VL - 3

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

M1 - 17022

ER -